Invention Grant
US08828381B2 Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
有权
共同给予CG250和IL-2或IFN-α用于治疗癌症如肾细胞癌
- Patent Title: Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas
- Patent Title (中): 共同给予CG250和IL-2或IFN-α用于治疗癌症如肾细胞癌
-
Application No.: US12559839Application Date: 2009-09-15
-
Publication No.: US08828381B2Publication Date: 2014-09-09
- Inventor: Sven Ole Warnaar , Stefan Ullrich
- Applicant: Sven Ole Warnaar , Stefan Ullrich
- Applicant Address: DE Munich
- Assignee: Wilex AG
- Current Assignee: Wilex AG
- Current Assignee Address: DE Munich
- Agency: Kilpatrick Townsend & Stockton LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K38/21 ; C07K16/30 ; A61K38/20 ; A61K38/00 ; A61K39/00
Abstract:
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.
Public/Granted literature
- US20100008888A1 CO-ADMINISTRATION OF CG250 AND IL-2 OR IFN-ALPHA FOR TREATING CANCER SUCH AS RENAL CELL CARCINOMAS Public/Granted day:2010-01-14
Information query
